KNIGHT THERAPEUTICS INC.

Management's Discussion and Analysis

For the quarter ended September 30, 2019

The following is Management's Discussion and Analysis of the financial condition and operating results of Knight Therapeutics Inc. ("Knight" or the "Company") for the three and nine months ended September 30, 2019. This document should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto for the three and nine months ended September 30, 2019 and the audited consolidated financial statements and Management's Discussion and Analysis of financial condition and operating results in our annual report for the year ended December 31, 2018. Knight's unaudited interim condensed consolidated financial statements as at and for the three and nine months ended September 30, 2019 have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting". All amounts herein are expressed in thousands of Canadian dollars (unless otherwise indicated) except for share and per share amounts. All other currencies are in thousands.

This discussion and analysis was prepared by management from information available as at November 12, 2019. Further information about Knight Therapeutics Inc., including the Annual Information Form, is available online on SEDAR at www.sedar.com.

Cautionary note regarding forward-looking statements

This Management's Discussion and Analysis may contain certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Factors and risks which could cause actual results to differ materially from current expectations are discussed in the Company's Annual Report and in the Company's Annual Information Form for the year ended December 31, 2018 found on SEDAR at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

TABLE OF CONTENTS

(In thousands of Canadian dollars, except for share and per share amounts)

GLOSSARY OF ABBREVIATIONS

Abbreviation	Calendar
Q3-19	Third quarter of 2019
Q2-19	Second quarter of 2019
Q1-19	First quarter of 2019
Q4-18	Fourth quarter of 2018
Q3-18	Third quarter of 2018
Q2-18	Second quarter of 2018
Q1-18	First quarter of 2018
Q4-17	Fourth quarter of 2017

Abbreviation	Company
60P	60^{o} Pharmaceuticals LLC
Advaxis	Advaxis Pharmaceuticals Inc.
Akorn	Akorn Inc.
Alimera	Alimera Sciences Inc.
Antibe	Antibe Therapeutics Inc.
Ardelyx	Ardelyx, Inc.
AstraZeneca	AstraZeneca AB
Biopas	Pharma Consulting Group
Braeburn	Braeburn Pharmaceuticals Inc.
Crescita	Crescita Therapeutics Inc.
Ember	Ember Therapeutics Inc.
Forbion	Forbion Capital Fund III CV
GBT	Biotoscana Investments S.A.
Jaguar	Jaguar Health Inc.
Karo	Karo Pharma AB
Knight or the Company	Knight Therapeutics Inc.
Medimetriks	Medimetriks Pharmaceuticals Inc.
Medison	Medison Biotech (1995) Ltd.
Moksha8	Moksha8, Inc.
NEMO II	New Emerging Medical Opportunities Fund II Ltd.
NEMO III	New Emerging Medical Opportunities Fund III Ltd.
NeurAxon	NeurAxon Pharma Inc.
PBB	Pro Bono Bio PLC
Profound	Profound Medical Inc.
Puma	Puma Biotechnology, Inc.
Sectoral	Sectoral Asset Management Inc.
SIFI	Società Industria Farmaceutica Italiana S.p.A.
Synergy	Synergy CHC Corp.
Titan	Titan Pharmaceuticals, Inc.
Triumvira	Triumvira Immunologics Inc.
TXMD	TherapeuticsMD, Inc.

Abbreviation	Financial
ASPP	Automatic share purchase plan for purchase of shares under the Normal Course Issuer Bid
BRL	Brazilian Real
C$ or $	Canadian Dollar
DC&P	Disclosure Controls and Procedures
EBITDA	Earnings before interest, tax, depreciation and amortization
EPS	Earnings per share to common shareholders
EUR	Euro
FMV	Fair market value
FVTPL	Fair value through profit or loss
ICFR	Internal control over financial reporting
IFRS	International Financial Reporting Standards
ILS	New Israeli Shekels
Interim Financial Statements	Unaudited interim condensed consolidated financial statements
US$	U.S. Dollar

Abbreviation	Territory
CAN	Canada
CAR	Select countries in the Caribbean
ISR	Israel
LATAM	Latin America
QUE	Quebec
ROM	Romania
RUS	Russia
UAE	United Arab Emirates
U.S.	United States of America
ZAF	Sub-Saharan Africa

Abbreviation	Other
AIDS	Acquired immune deficiency syndrome
ART	Antiretroviral Therapy
CADTH	Canadian Agency For Drugs And Technologies In Health
CEO	Chief executive officer
HIV	Human immunodeficiency virus infection
IBS-C	Irritable Bowel Syndrome with Constipation
IQVIA	IQVIA Incorporated, a leading pharmaceutical market research organization
NCIB	Normal Course Issuer Bid
NDA	New Drug Application
NDS	New Drug Submission
NIHB	Non-Insured Health Benefits for First Nations and Inuit Program
NON	Notice of Non-Compliance
OIC	Opioid-induced constipation
pERC	Pan-Canadian Oncology Drug Review Expert Review Committee
PMPRB	Patented Medicine Prices Review Board
PRV	Priority Review Voucher

OVERVIEW

Section 1 – About Knight Therapeutics Inc.

Knight Therapeutics Inc. is a specialty pharmaceutical company, headquartered in Montreal, Canada, and listed on the Toronto Stock Exchange under the ticker symbol "GUD". Activities performed by the Company are as follows:

- Principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets.
- Finances other life sciences companies with the goal of strengthening relationships in the life science industry and securing product distribution rights for Canada and select international markets.
- Invested in life sciences venture capital funds whereby the Company may receive preferential access to innovative healthcare products for Canada and select international markets.
- Develops innovative pharmaceutical products including those to treat neglected tropical and rare pediatric diseases.

Section 2 – Q3-19 Highlights

Financial Results

- Revenues were $4,030, an increase of $810 or 25% over prior year.
- Net loss was $2,959 compared to net income of $12,930 in prior year.

Corporate Development

- Launched a NCIB in July 2019 and purchased 7,174,137 common shares for an aggregate cost of $54,283.

Products

- Received regulatory approval from Health Canada for NERLYNX® for the treatment of HER2-positive breast cancer.
- Reached an agreement with the pan-Canadian Pharmaceutical Alliance regarding Probuphine® and to date have obtained reimbursement through public insurance plans administered by Alberta, Saskatchewan, New Brunswick, Manitoba, Veterans Affairs Canada and the NIHB.

Strategic Investments

- Disposed of 899,200 common shares of Crescita for total proceeds of $916.

Subsequent to quarter-end

- Entered into a definitive agreement to acquire 51.2% of Biotoscana Investments S.A., a company operating in LATAM. Following the close of the agreement, Knight will launch a mandatory tender offer to acquire the remaining 48.8% from public shareholders on similar terms. Upon completion of both transactions and assuming all public shares are tendered, Knight expects to have paid approximately $418,000[1] [BRL 1,318,000], including net debt.
- Received regulatory approval from Health Canada for Netildex® for the treatment of inflammatory ocular conditions of the anterior segment of the eye.
- Submitted Joyesta™ for regulatory approval for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency to Health Canada.

[1]Amount translated at the BRL to CAD closing exchange rate as of October 18, 2019 of 3.145. The price in Canadian dollars will vary depending on the exchange rate on the date of the transactions.

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL RESULTS

Section 3 – Results of Operations

	Q3-19	Q3-18	Change $[1]	Change %[2]	YTD-19	YTD-18	Change $[1]	Change %[2]
Revenues	**4,030**	3,220	810	25%	**10,190**	8,612	1,578	18%
Cost of goods sold	**750**	609	(141)	23%	**1,752**	1,781	29	2%
Gross margin	**3,280**	2,611	669	26%	**8,438**	6,831	1,607	24%
Gross margin (%)	***81%***	*81%*	*0%*	*0%*	***83%***	*79%*	*4%*	*5%*
Expenses								
Selling and marketing	**1,125**	1,000	(125)	13%	**3,260**	2,681	(579)	22%
General and administrative	**4,649**	1,833	(2,816)	154%	**12,034**	5,865	(6,169)	105%
Research and development	**892**	438	(454)	104%	**2,502**	1,499	(1,003)	67%
	(3,386)	(660)	(2,726)	413%	**(9,358)**	(3,214)	(6,144)	191%
Depreciation of property and equipment	**112**	28	(84)	300%	**305**	63	(242)	384%
Amortization of intangible assets	**424**	481	57	12%	**1,273**	1,367	94	7%
Interest income on financial instruments measured at amortized cost	**(4,825)**	(3,864)	961	25%	**(14,651)**	(10,956)	3,695	34%
Other interest income	**(1,233)**	(1,092)	141	13%	**(3,457)**	(4,034)	(577)	14%
Other income	**(1,579)**	(385)	1,194	310%	**(1,949)**	(1,773)	176	10%
Net loss (gain) on financial assets measured at fair value through profit or loss	**4,883**	(10,924)	(15,807)	N/A	**(19,649)**	(14,349)	5,300	37%
Share of net income of associate	**(128)**	(89)	39	44%	**(448)**	(441)	7	2%
Foreign exchange loss (gain)	**638**	1,117	479	43%	**3,315**	(1,431)	(4,746)	N/A
Income before income taxes	**(1,678)**	14,068	(15,746)	N/A	**25,903**	28,340	(2,437)	9%
Income tax expense (recovery)								
Current	**999**	1,891	892	47%	**3,168**	3,443	275	8%
Deferred	**282**	(753)	(1,035)	N/A	**1,549**	1,039	(510)	49%
Net (loss) income for the period	**(2,959)**	12,930	(15,889)	N/A	**21,186**	23,858	(2,672)	11%
Attributable to shareholders of the Company								
Basic net (loss) earnings per share	**(0.021)**	0.091	(0.112)	N/A	**0.150**	0.167	(0.017)	10%
Diluted net (loss) earnings per share	**(0.021)**	0.090	(0.111)	N/A	**0.150**	0.167	(0.017)	10%

[1] *A positive variance represents a positive impact to net income and a negative variance represents a negative impact to net income*
[2] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-19 vs Q3-18	YTD-19 vs YTD-18
Revenues	• Increase in revenues mainly attributable to timing of sales of Impavido® and growth in Movantik® sales.	
Gross margin	• Increase in gross margin ($) attributable to increase in revenues. • No significant variance in gross margin (%).	• Increase in gross margin ($) attributable to increase in revenues. • Increase in gross margin (%) attributable to change in product mix.
Selling and marketing	• No significant variance.	• Increase due to commercial activities including preparation for launch of new products.
General and administrative	• Increase mainly due to following: • Expense of $3,803 (Q3-19: $536) on legal, consulting and advisory fees to Knight's shareholder & communication advisor, financial advisor and lawyers related to the activist campaign, public proxy battle and related litigations (refer to section 26 for further details) between the Company and dissident shareholder Meir Jakobsohn, Medison's CEO. • Expense of $2,476 on legal & consulting fees related to the acquisition of GBT. Knight expects to incur additional expenses related to the acquisition during the remainder of the year and in 2020.	
Research and development expenses	• Increase mainly due to submission of Joyesta™ for regulatory approval to Health Canada.	• Increase mainly due to submission of Ibsrela™ and Joyesta™ for regulatory approval to Health Canada.
Depreciation and amortization	• No significant variance.	
Interest income	• Includes "Interest income on financial instruments measured at amortized cost" and "Other interest income". • Primarily from interest earned on loans, cash and cash equivalents, marketable securities and accretion on loans receivable. • Interest income for Q3-19 was $6,058, an increase of 22% or $1,102 compared to the same period in prior year due to a higher average loan balance and an increase in interest rates, offset by a decrease in the average cash and marketable securities balances.	• Interest income for YTD-19 was $18,108 an increase of 21% or $3,118 compared to the same period in prior year due to a higher average loan balance and an increase in interest rates, offset by a decrease in the average cash and marketable securities balances.
Other income[1]	• Amount in Q3-19 driven by fees earned on strategic loan deals and a fee earned through a strategic fund investment. • Amount in Q3-18 driven by the repayment fee of the Profound loan.	• Amount in YTD-19 driven by fees earned on strategic loan deals and a fee earned through a strategic fund investment. • Amount in YTD-18 driven by the early repayment fees on the Medimetriks and Profound loans.
Net loss (gain) on financial assets measured at fair value through profit or loss	• As a result of the revaluation of financial assets measured at FVTPL. • Net loss mainly attributed to the unrealized losses on revaluation of the strategic fund and equity investments, offset by changes in fair values of strategic loans • Refer to note 7 in the Interim Financial Statements for further information.	• Net gain mainly attributed to the unrealized gains on revaluation of the strategic fund investments, offset by changes in fair values of strategic loans.
Share of net income of associate	• No significant variance.	
Foreign exchange loss (gain)	• Due to relative losses on certain CAD and EUR dollar denominated financial assets as Canadian dollar weakened.	• Due to relative losses on certain U.S. dollar denominated financial assets as Canadian dollar strengthened.
Income tax expense (recovery)	• No significant variance.	

[1] *Other income includes income earned for advisory and other services, gains from early loan repayments and income from strategic lending deals*

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL CONDITION

Section 4 – Balance Sheets

	09-30-19	12-31-18	Change $	Change %[1]
ASSETS				
Current				
Cash and cash equivalents	**319,125**	244,785	74,340	30%
Marketable securities	**243,790**	445,003	(201,213)	45%
Trade and other receivables	**12,644**	11,756	888	8%
Inventories	**472**	1,136	(664)	58%
Other current financial assets	**22,758**	14,030	8,728	62%
Income taxes receivable	**729**	821	(92)	11%
Total current assets	**599,518**	717,531	(118,013)	16%
Marketable securities	**137,177**	97,274	39,903	41%
Property and equipment	**1,679**	794	885	111%
Intangible assets	**18,948**	17,475	1,473	8%
Other financial assets	**148,323**	113,314	35,009	31%
Investment in associate	**73,729**	79,145	(5,416)	7%
Deferred income tax assets	**1,305**	2,959	(1,654)	56%
Other receivable	**41,582**	23,340	18,242	78%
Total assets	**1,022,261**	1,051,832	(29,571)	3%
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current				
Accounts payable and accrued liabilities	**9,298**	6,100	3,198	52%
Automatic share purchase plan liability	**35,987**	—	35,987	N/A
Lease liabilities	**298**	—	298	N/A
Income taxes payable	**12,587**	10,705	1,882	18%
Other balances payable	**100**	197	(97)	49%
Deferred other income	—	183	(183)	100%
Total current liabilities	**58,270**	17,185	41,085	239%
Lease liabilities	**703**	—	703	N/A
Other balances payable	**5,109**	4,615	494	11%
Total liabilities	**64,082**	21,800	42,282	194%
Shareholders' equity				
Share capital	**698,115**	761,844	(63,729)	8%
Warrants	**785**	785	—	—
Contributed surplus	**15,965**	14,326	1,639	11%
Accumulated other comprehensive income	**15,909**	20,955	(5,046)	24%
Retained earnings	**227,405**	232,122	(4,717)	2%
Total shareholders' equity	**958,179**	1,030,032	(71,853)	7%
Total liabilities and shareholders' equity	**1,022,261**	1,051,832	(29,571)	3%

[1] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

	09-30-19 vs 12-31-2018
Cash and cash equivalents and marketable securities (current and long term)	• Refer to Section 6 – Liquidity and Capital Resources for further information.
Trade and other receivables	• Increase due to timing of collection of payments. • Refer to note 5 in the Interim Financial Statements for further details.
Inventories	• No significant variance.
Other financial assets (current and long term)	• Increase of $43,737 driven by: **Loans and other receivables:** increase of $10,869 mainly attributable to additional loans issued of $23,295 driven by the Moksha8 and Triumvira deals, partially offset by loan repayments of $6,208 and changes in fair value and foreign exchange revaluation of $6,218. Refer to Section 7 for further information on Knight's strategic lending portfolio. **Equities, Warrants and Derivatives:** increase of $1,785 driven by additional warrants obtained during the year and the revaluation of equities, warrants and derivatives. Refer to note 7 in the Interim Financial Statements for further information. **Funds:** increase of $31,083 due to capital calls of $18,434 and mark-to-market adjustments of $25,733 offset by distributions received of $9,177 and foreign exchange losses of $3,907. Refer to Section 9 for further information on Knight's strategic investments.
Income tax receivable	• No significant variance.
Property and Equipment	• Increase due to recognition of lease assets with the adoption of IFRS 16. • Refer to note 2 in the Interim Financial Statements for further information.
Intangible assets	• Increase due to in-licensing activity, offset by amortization. • Refer to note 6 in the Interim Financial Statements for further details.
Investment in associate	• Decrease related to dividends received from Medison and Knight's share of other comprehensive income partially offset by Knight's share of net income. • Refer to Section 10 for further information.
Other receivable	• Increase due to deposit of $18,242 made to the QRA related to a notice of reassessment. Refer to Section 5 for further information.
Accounts payable and accrued liabilities	• Increase due to timing of purchases and payments.
Automatic share purchase plan liability	• Balance related to the obligation to repurchase common shares of Knight under the NCIB and through the ASPP. • Refer to note 11 in the Interim Financial Statements for further information.
Lease Liabilities	• Increase due to the adoption of IFRS 16. • Refer to section 23 and note 2 in the Interim Financial Statements for further information.
Income tax payable	• Increase due to income and gains generated.
Deferred other income	• No significant variance.
Other balances payable (current and long term)	• Increase due to recognition of regulatory and sales milestones on in-licensed products.
Share capital	• Decrease due to the purchase of Knight's common shares though the NCIB. • Refer to note 11 in the Interim Financial Statements for further information.
Contributed surplus	• Increase related to share-based compensation expense. • Refer to the statement of changes in shareholders' equity in the Interim Financial Statements for further information.
Accumulated other comprehensive income	• Decrease related to other comprehensive loss of $5,046 for the period. • Refer to the statement of changes in shareholders' equity in the Interim Financial Statements for further information.

(In thousands of Canadian dollars, except for share and per share amounts)

	09-30-19 vs 12-31-2018
Retained earnings	• Decrease due to Knight's common shares purchased through the NCIB, partially offset by net income of $21,186 in 2019.

Section 5 – Notices of Reassessment

Knight received notices of reassessment from the CRA and the QRA in July 2018 and January 2019 respectively. The notices relate to the disposition in 2014 of a PRV held by Knight's wholly-owned subsidiary, Knight Therapeutics (Barbados) Inc. A PRV is a transferrable asset that entitles the holder to a priority review for a drug of its choice.

The Company's PRV was granted on March 19, 2014 upon the FDA approval of Impavido® and was disposed of to a third party in November 2014 for gross proceeds of US$125,000. The notices of reassessment provide that Knight is liable to pay an aggregate of $23,340 and $18,242 to the CRA and QRA respectively in additional taxes and interest. Knight has made a deposit for the full amount to the CRA in July 2018 and to the QRA in February 2019.

Knight believes that the reassessments are unfounded and filed a notice of objection with CRA in September 2018 to start the appeals process. Based on the Company's view of the likely outcome of the appeals process, Knight expects to recover the total of $41,582 deposited and has not recorded any tax provision related to the disposal of the PRV in its financial statements. However, there can be no assurance regarding the outcome or when a resolution may be reached.

Although Knight believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accruals.

Section 6 – Liquidity and Capital Resources

The Company's Investment Policy governs the investment activities relating to cash resources. An Investment Committee composed of representatives from management and the Board of Directors monitors compliance with said policy. The Company invests in strategic investments in the form of equity funds, debt funds, equity or liquid investment securities with varying terms to maturity, selected with regard to the expected timing of investments and expenditures for continuing operations and prevailing interest rates.

The Company believes that its existing cash, cash equivalents and marketable securities as well as cash generated from operations are sufficient to finance its current operations, working capital requirements and future product and corporate acquisitions. The table below sets forth a summary of cash flow activity and should be read in conjunction with our consolidated statements of cash flows.

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2019	2018	**$**	**%**[1]	**2019**	2018	**$**	**%**[1]
Net cash from operating activities	**4,028**	(19,916)	23,944	N/A	**(2,908)**	(8,992)	6,084	68%
Net cash from investing activities	**73,113**	(93,420)	166,533	N/A	**132,274**	(188,209)	320,483	N/A
Net cash from financing activities	**(53,762)**	148	(53,910)	N/A	**(53,783)**	239	(54,022)	N/A
Increase (decrease) in cash and cash equivalents during the period	**23,379**	(113,188)	136,567	N/A	**75,583**	(196,962)	272,545	N/A
Net foreign exchange difference	**835**	(1,948)	2,783	N/A	**(1,243)**	3,724	(4,967)	N/A
Cash and cash equivalents, beginning of the period	**294,911**	418,358	(123,447)	30%	**244,785**	496,460	(251,675)	51%
Cash and cash equivalents, end of the period	**319,125**	303,222	15,903	5%	**319,125**	303,222	15,903	5%
Marketable securities, end of the period	**380,967**	471,824	(90,857)	19%	**380,967**	471,824	(90,857)	19%
Cash, cash equivalents, and marketable securities, end of the period	**700,092**	775,046	(74,954)	10%	**700,092**	775,046	(74,954)	10%

[1] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-19 vs Q3-18	YTD-19 vs YTD-18
Net cash from operating activities	Primarily relates to cash generated through revenues, dividends from associates and interest received, offset by operating expenses including salaries, research and development expenses, advertising and promotion costs, and other corporate expenses. In addition, Knight deposited $18,242 to the QRA related to the sale of the PRV in 2014. Cash flows from operating activities exclude revenues and expenses not affecting cash, such as unrealized and realized gains or losses on financial assets, accretion of interest, share based compensation expense, depreciation and amortization, foreign exchange gains or losses, share of net income and dividends from associate, other income, deferred other income, and net changes in non-cash balances relating to operations.	
Net cash from investing activities	For the three-month period ended September 30, 2019, cash flows were mainly driven by: • net proceeds on marketable securities of $70,243; • net proceeds from distributions of funds of $2,636; • net proceeds from disposals of equities of $1,676, offset by • net issuance of loan receivables of $1,114; • acquisition of intangibles of $328.	For the nine-month period ended September 30, 2019, cash flows were mainly driven by: • net proceeds on marketable securities of $158,646, • net proceeds from disposals of equities of $1,670, offset by; • net issuance of loan receivables of $16,464; • net investments in life sciences funds of $9,257; • acquisition of intangibles and property and equipment of $2,321.
Net cash from financing activities	Cash flows from financing activities were mainly due to the repurchase of common shares through the NCIB, proceeds from the repayment of share purchase loans and the participation of employees and directors in the Company's share purchase plan.	

PRODUCT ACQUISITION STRATEGY

Section 7 – Products

Knight pursues opportunities to acquire or in-license pharmaceutical products, consumer health products and medical devices in Canada and select international markets. Knight's wholly owned subsidiary in Barbados develops innovative pharmaceuticals including those used to treat neglected tropical diseases and rare pediatric diseases. Knight expects to expand its product portfolio within existing therapeutic fields in Canada and internationally, and intends to leverage its expertise in specialty sales and marketing, product acquisition and in-licensing to gain a competitive advantage in delivering pharmaceutical products to the marketplace, thereby decreasing scientific risks, long development timelines and high development costs.

Knight has a pipeline of products in the process of being submitted for regulatory approval, in pre-commercialization and at its early stages of commercialization. Such activities require substantial financial investment therefore it is expected that the Company's selling & marketing and research & development expenses will increase. The following table summarizes certain products from Knight's product portfolio.

Prescription Pharmaceutical Products

Product	Indication/Potential Indication	Licensor	Status in Territory	Territory Rights
Pain/Gastrointestinal				
Movantik®	OIC	AstraZeneca	Marketed in CAN and approved in ISR	CAN, ISR
Probuphine®	Opioid addiction	Titan	Marketed	CAN
Ibsrela™	IBS-C	Ardelyx	Submitted	CAN

Prescription Pharmaceutical Products (continued)

Product	Indication/Potential Indication	Licensor	Status in Territory	Territory Rights
Pain/Gastrointestinal (continued)				
Mytesi™	Symptomatic relief of non-infectious diarrhea in adult patients with HIV or AIDS on ART	Jaguar	Pending submission	CAN, ISR
	Other diarrhea disorders		Pre-clinical – Phase 2	
NeurAxon family	Acute migraine, pain and neurological disorders	N/A	Pre-Clinical – Phase 2	CAN, ISR, RUS, ZAF
Antibe family	Chronic pain and inflammation	Antibe	Pre-clinical – Phase 2	CAN, ISR, RUS, ZAF
Oncology				
NERLYNX®	HER2-positive breast cancer	Puma	Approved	CAN
Advaxis family	HPV-associated cancers and others	Advaxis	Phase 1 – Phase 3	CAN
Triumvira family	Novel T-cell therapies for cancer	Triumvira	Pre-clinical	CAN[2], ISR, MEX, BRA, COL
Ophthalmic				
AzaSite™	Bacterial conjunctivitis	Akorn	Approved	CAN
Iluvien®	Diabetic macular edema	Alimera	Approved	CAN
Netildex®	Ocular inflammation	SIFI	Approved	CAN
Women's Health				
Joyesta™	Moderate-to-severe dyspareunia	TXMD	Submitted	CAN, ISR
Bijuva™	Moderate-to-severe vasomotor symptoms due to menopause	TXMD	Pending submission	CAN, ISR
Other				
Impavido®	Leishmaniasis	N/A	Marketed	Global
Burinex®	Edema associated with congestive heart failure, cirrhosis of the liver and renal disease	Karo	Marketed	CAN
Arakoda™	Prevention of malaria	60P	Pending submission	CAN, ISR, RUS, LATAM[1]
60P family	Other tropical diseases	60P	Phase 2	CAN, ISR, RUS, LATAM[1]
Tenapanor	Hyperphosphatemia	Ardelyx	Phase 3	CAN

[1] Select products only for LATAM
[1] Excluded TACO1-CD19

(In thousands of Canadian dollars, except for share and per share amounts)

Consumer Health Products and Medical Devices

Product	Description	Licensor	Status in Territory	Territory Rights
Neuragen®	Pain associated with diabetic and peripheral neuropathy	N/A	Marketed[1]	Global (Ex. U.S)
Synergy Family	Various consumer health products	Synergy	Marketed[2]	CAN, ISR, ROM, RUS, ZAF
FLEXISEQ™	Pain and joint stiffness associated with osteoarthritis	PBB	Not Yet Marketed	QUE, ISR
Crescita family	Dermo-cosmetic line of products	Crescita	Not Yet Marketed	ISR, ROM, RUS, ZAF, CAR
TULSA-PRO®	Prostate ablation	Profound	Pending submission	CAN

[1] *Approved and marketed in Canada and the UAE*
[2] *Select products marketed*

Movantik®

In December 2016, Knight entered into an agreement with AstraZeneca for the rights to Movantik® in Canada and Israel under which Knight is responsible for all commercial, regulatory and certain supply chain activities. Movantik® is the first once-daily oral peripherally-acting mu-opioid receptor antagonist for the treatment of OIC in adult patients with non-cancer pain who have had an inadequate response to laxatives. According to the Canadian Family Physician Practice Guideline, it is estimated that at least 26% of chronic opioid users suffer from OIC. According to IQVIA data, Movantik® sales in Canada were $419 and $1,169 for the three and nine-month periods ended September 30, 2019 (2018: $343 and $963).

Probuphine®

On February 1, 2016, Knight entered into an exclusive licensing agreement with Braeburn to commercialize Probuphine® in Canada. Probuphine®, indicated for the treatment of opioid drug dependence, is a subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention. Health Canada approved Probuphine® on April 18, 2018 for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support. Probuphine® must be inserted and removed by a healthcare professional who has successfully completed the Probuphine® Education Program.

On October 29, 2018, Knight launched Probuphine® in Canada. Furthermore, in August 2019, the Company reached an agreement with the pan-Canadian Pharmaceutical Alliance and to date has obtained reimbursement of Probuphine® through public insurance plans administered by Alberta, Saskatchewan, New Brunswick, Manitoba, Veterans Affairs Canada, and the NIHB. Knight's commercial focus for the remainder of the year will be on reimbursement in additional jurisdictions and physician training.

Tenapanor

On March 16, 2018, Knight entered into an exclusive licensing agreement with Ardelyx to commercialize tenapanor in Canada. Tenapanor is a first-in-class small molecule treatment that has completed Phase 3 development for IBS-C (marketed as Ibsrela™) and is in an ongoing Phase 3 study for hyperphosphatemia. Ardelyx received regulatory approval for Ibsrela™ from the US FDA in September 2019. On June 26, 2019, Ibsrela™ was accepted for review by Health Canada.

Jaguar

On September 24, 2018, Knight entered into a distribution, license and supply agreement with Jaguar that grants Knight the exclusive right to commercialize Mytesi® (crofelemer 125 mg delayed-release tablets) and related products in Canada and Israel and a right of first negotiation to commercialize Mytesi® and related products in specified Latin American countries. Mytesi® is a FDA-approved product in the U.S. indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV or AIDS on ART.

Antibe family

On November 13, 2015, Knight entered into an exclusive long-term license and distribution agreement with Antibe to commercialize its anti-inflammatory and pain product pipeline, along with certain future Antibe products, in Canada and select countries. On March 20, 2018, Antibe announced that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal safety study. On January 21, 2019, Antibe announced that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The primary objective of the study is to evaluate the efficacy of ATB-346 in reducing osteoarthritis pain over a 14-day treatment period.

Iluvien®

On July 21, 2015, Knight entered into an agreement with Alimera pursuant to which Knight acquired the exclusive Canadian distribution rights to Iluvien®, a sustained release intravitreal implant for the treatment of diabetic macular edema. Iluvien® was approved by Health Canada on November 26, 2018 for the treatment of diabetic macular edema. In September 2019 CADTH published their final report recommending that Iluvien® should not be reimbursed through the public insurance plans. Knight is working with Alimera to assess the resubmission process.

Netildex®

On August 2, 2016, Knight entered into a license agreement for the exclusive rights in Canada to commercialize Netildex®, a fixed combination of netilmicin and dexamethasone, that is indicated in adult patients (including the elderly) for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate. Netildex® was approved by Health Canada on October 23, 2019.

NERLYNX®

On January 9, 2019, Knight entered into an exclusive license agreement with Puma for the exclusive right to commercialize NERLYNX® (neratinib) in Canada. On July 16, 2019, NERLYNX® was approved by Health Canada for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Furthermore, in July 2019, Puma has submitted a supplemental NDA to the U.S. FDA for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments. Knight plans to launch NERLYNX® in late 2019. In October 2019 pERC published their initial report recommending that NERLYNX® should not be reimbursed through the public insurance plans. The Company has filed a feedback to the initial recommendation and is expecting a response from pERC by the end of 2019.

Triumvira family

On February 20, 2019 Knight entered into a secured loan and exclusive license agreement with Triumvira to commercialize its future approved products for Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia. Triumvira is developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.

TXMD

On July 31, 2018, Knight entered into an exclusive licensing agreement for the commercial rights of Joyesta™ and Bijuva™ in Canada and Israel. Joyesta™ is a TXMD FDA-approved product, marketed as Imvexxy™ (estradiol vaginal inserts) in the U.S., for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Bijuva™ was approved by the U.S. FDA on October 18, 2018, is a bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. On October 30, 2019, Knight announced that Joyesta™ was accepted for review by Health Canada. Knight expects to submit the NDS in Canada for Bijuva™ in 2019.

(In thousands of Canadian dollars, except for share and per share amounts)

Impavido®

On February 27, 2014, Knight acquired the worldwide rights to Impavido® as part of its business separation agreement with Paladin. Impavido® is an oral drug treatment based on miltefosine for the visceral, cutaneous and mucocutaneous leishmaniasis which is caused by a protozoa parasite from over 20 Leishmania species and is approved for sale in the U.S, Germany and Israel. Impavido® was launched in the U.S in March 2016 by Knight's commercialization partner, Profounda. On August 1, 2018, Knight out-licensed the commercial rights of Impavido® for the territories of Colombia, Peru, Ecuador and Paraguay to Biopas.

Arakoda™

On December 10, 2015, the Company entered into a loan agreement with 60P for the development of tafenoquine for the prevention of malaria in adults. As consideration for the loan, Knight received the commercial rights of the Product for Canada, Israel, Russia and LATAM. The Product was approved by the FDA on August 9, 2018.

Burinex®

On April 26, 2019, the Company entered into a distribution agreement with Karo for Burinex®, a product indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Under the agreement Knight will earn a nominal distribution fee on the sales of Burinex®.

Section 8 – Strategic Lending

Knight finances other life sciences companies in all geographic markets with the goal of strengthening relationships in the life sciences industry and securing product distribution rights for Canada and select international markets. Typically, loans have low double-digit interest rates and may come with additional consideration to the Company. Loans often come with product rights or product options for Canada and select international markets. These loans strengthen Knight's ties within the life sciences industry and, in doing so, help to secure product rights for Knight either on a direct or indirect basis. As of the date hereof, Knight has seven secured loans outstanding to life sciences companies as outlined in the table below. To date, the strategic lending portfolio has led to the acquisition or in-licensing of Knight's consumer health products (as described in Section 7), the Antibe family, the 60P family, TULSA-PRO® and the Triumvira family.

	Nominal loan balance as at September 30, 2019	
Entity	**In Source Currency**	**In Canadian Dollars[1]**
Moksha8	US$11,993	$15,883
Synergy	US$6,000	$7,946
60P[2]	US$6,810	$9,018
Triumvira	US$5,000	$6,622
Crescita	C$3,639	$3,639
Ember	US$500	$662
Total		**$43,770**

[1] *Converted at the Bank of Canada closing exchange rates on September 30, 2019*

[2] *Excludes 60P Convertible Debenture received as consideration for loans issued to 60P*

As at September 30, 2019, the nominal loan balance outstanding was $43,770, including $40,131 [US$30,303] (September 30, 2018: $24,913, including $20,025 [US$15,469]). The following table summarizes the movement in loans and other receivables during the nine-month period ended September 30.

(In thousands of Canadian dollars, except for share and per share amounts)

	Carrying value as at January 1 $	Additions $	Loan repayments $	Net (loss) gain on FA[1] $	Foreign exchange[2,3] $	Carrying value end of period $	Current other financial assets $	Non-current other financial assets $
2019								
Amortized Cost	2,964	2,046	(2,684)	—	(101)	2,225	—	2,225
FVTPL	24,711	21,249	(3,524)	(5,676)	(441)	36,319	14,121	22,198
Total	**27,675**	**23,295**	**(6,208)**	**(5,676)**	**(542)**	**38,544**	**14,121**	**24,423**

[1] Net changes related to change in the fair value of loan receivables and recognition of day 1 gains
[2] Recorded a loss of $2 in the statement of income in "Foreign exchange loss (gain)" (2018: gain of $870) and a loss of $540 in the statement of other comprehensive income in "Unrealized (loss) gain on translation of foreign operations" (2018: gain of $619)
[3] During the three-month period ended September 30, 2019, recorded a gain of $246 in the statement of income in "Foreign exchange loss (gain)" (2018: loss of $47) and a gain of $141 in the statement of other comprehensive income in "Unrealized (loss) gain on translation of foreign operations" (2018: loss of $326)

Moksha8

On October 17, 2018 the Company entered into a strategic relationship with Moksha8, a specialty pharmaceutical company operating in Brazil and Mexico, through the issuance of a $2,599 [US$2,000] promissory note bearing an annual interest of 15%. The promissory note was recorded using the amortized cost method and was repaid in February 2019.

On February 15, 2019, the Company entered into a financing agreement with Moksha8 for up to $170,525 [US$125,000] ("Financing Agreement"), of which $13,134 [US$10,000] was initially issued. The loan disbursed was recorded at a relative fair value of $13,449 [US$10,213] upon initial measurement and subsequently accounted for at FVTPL. The loan bears interest at 15% per annum and matures five years from the issuance date. Furthermore, Knight received warrants representing 5% of the fully diluted shares of Moksha8.

On September 30, 2019, the Company loaned an additional $1,987 [US$1,500] as an advance of a future loan commitment to Moksha8 at an interest rate of 15% per annum. The loan matures in 2021 and was recorded at its nominal value which represents fair value and will subsequently be accounted at amortized cost. As at September 30, 2019, the total nominal loan balance outstanding was $15,883 [US$11,993].

Under the terms of the Financing Agreement, Knight has a remaining loan commitment of $13,905 [US$10,500] which will be disbursed upon Moksha8 meeting pre-defined profitability targets. In addition, the Company may issue an additional $132,430 [US$100,000] at Knight's sole discretion for corporate development and the acquisition of product licenses.

Triumvira

On February 20, 2019, the Company entered into a secured loan agreement with Triumvira for $6,585 [US$5,000] for the development of its novelty T cell therapies ("Triumvira Loan Agreement"). The loan bears interest at 15% per annum and matures on February 20, 2020. The loan was recorded at a relative fair value of $6,264 [US$5,000] upon initial measurement and subsequently accounted for at FVTPL. In addition, Knight received warrants to purchase 3.5% of Triumvira's fully diluted common shares and the exclusive right to commercialize Triumvira's future approved products in Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia.

Medimetriks

During 2016, Knight issued $31,290 [US$23,000] to Medimetriks in secured loans to support its acquisition of the exclusive U.S. development and commercialization rights of OPA-15406 from Otsuka. On March 7, 2018, Knight received an early repayment of principal of $25,894 [US$20,000] and interest and fees of $3,569 [US$2,757]. Subsequent to the early repayment and scheduled principal repayments of $2,923 [US$2,250], the outstanding loan balance was $1,005 [US$750]. The remaining loan balance was repaid in full on June 18, 2019.

(In thousands of Canadian dollars, except for share and per share amounts)

Section 9 – Strategic Investments

Fund Investments

Knight invests in life sciences venture capital funds in which the Company earns a return similar to any other limited partner in the fund and may receive preferential access to innovative healthcare products from around the world for Canada and select international markets. Since inception of the fund strategy, Knight has committed to invest with the following capital fund managers for approximately $126,653 of which $45,830 remains committed as at September 30, 2019. To date, the investments in venture capital funds have led to the Canadian in-license of Iluvien® from Alimera and a portfolio of products from Advaxis. Knight does not expect to invest in additional venture capital funds.

	Fund Commitments	
Entity	**In Source Currency**	**In Canadian Dollars[1]**
Teralys Capital	C$30,000	$30,000
Domain Associates LLC	US$25,000	$29,063
Forbion Capital Partners	EUR 19,500	$27,550
Sectoral Asset Management[2]	US$13,000	$13,919
Sanderling Ventures LLC	US$10,000	$11,625
HarbourVest Partners LLC	C$10,000	$10,000
TVM Capital GmbH	US$1,600	$1,996
Bloom Burton Healthcare Lending Trust[3]	C$1,500	$1,500
Genesys Capital Management (Fund III) Inc.	C$1,000	$1,000
Total		**$126,653**

[1] Converted at the Bank of Canada noon exchange rates as of the commitment date (using the September 30, 2019 closing rates total fund commitment would be $136,275)
[2] Knight received a full return of capital from its US$13,000 investment in Sectoral's NEMO II and subsequently committed to reinvest US$10,000 into Sectoral's NEMO III
[3] Represents an investment in a debt fund

Since the inception of the strategic fund investments, the Company invested $113,272 and received distributions of $47,953 on which a gain of $15,486 was realized. Furthermore, as at September 30, 2019, the fund investments were recorded at their fair value of $118,137 representing a cumulative unrealized gain of $52,818. The following table summarizes the movement in fund investments during quarter ended September 30, 2019.

	Carrying value as at January 1 $	Additions[1] $	Distributions[2] $	Net gain on FA $	Foreign exchange[3,4] $	Carrying value end of period $	Current other financial assets $	Non-current other financial assets $
2019	**87,054**	**18,434**	**(9,177)**	**25,733**	**(3,907)**	**118,137**	**—**	**118,137**

[1] Investments in equity or debt funds including US$3,301 and EUR 2,642 (2018: including US$6,668 and EUR 2,686)
[2] Distributions received from funds including US$1,665 and EUR 724 (2018: including US$1,275 and EUR 2,586)
[3] Recorded a loss of $2,134 in the statement of income in "Foreign exchange loss (gain)" (2018: gain of $348) and $1,773 in the statement of other comprehensive income in "Unrealized (loss) gain on translation of foreign operations" (2018: gain of $995)
[4] During the three-month period ended September 30, 2019, recorded a loss of $1,082 in the statement of income in "Foreign exchange loss (gain)" (2018: loss of $123) and a gain of $855 in the statement of other comprehensive income in "Unrealized (loss) gain on translation of foreign operations" (2018: gain of $894)

(In thousands of Canadian dollars, except for share and per share amounts)

Other investments

Investment in Crescita

During the quarter ended September 30, 2019, Knight disposed of 899,200 common shares of Crescita at an average price of $1.02 per share for total proceeds of $916. The common shares sold were previously acquired by Knight at an average cost of $0.60 per share. As at September 30, 2019, Knight owned an aggregate of 1,935,489 common shares and 396,000 warrants of Crescita.

For additional details regarding the movement in equities or derivatives held by Knight throughout the quarter, refer to note 7 "Other Financial Assets" of the Interim Financial Statements.

Section 10 – Rest of World Strategy

Knight's international strategy is focused on identifying potential products and companies that fit within its existing business model, but that are located in select areas such as Israel, Latin America, Middle East, Australia, Romania, Russia, Sub-Saharan Africa, and other countries excluding the U.S., Western Europe, Japan and China. Knight intends to continue its growth by becoming an international specialty pharmaceutical company and believes that these countries provide potentially significant growth and value opportunities.

Expansion in LATAM

Subsequent to the quarter ended September 30, 2019, the Company has entered into a definitive agreement to acquire 51.2% of GBT. For further details refer to Section 27.

Investment in Medison

On September 9, 2015, Knight acquired a 28.3% ownership interest in Medison, a privately-owned specialty pharmaceutical company based in Israel. The consideration given for the equity interest in Medison amounted to $82,001, which includes the fair value of 10,330,884 common shares of Knight issued to Medison and its controlling shareholder and a contingent consideration of $1,100. In addition, the Company incurred $217 of transaction costs which were capitalized with the investment. On June 16, 2016, the Company issued 250,000 common shares at a price of $8.29 per share for $2,073 and reduced the amount of contingent consideration recorded in contributed surplus upon the initial investment in Medison by $943. Consequently, the Company recorded an increase of $1,130 in the investment in associate. There is no further contingent consideration payable to Medison.

The interest in Medison is accounted for using the equity method of accounting. The investment was originally recorded at cost and subsequently adjusted to include the Company's share of Medison's net income and any dividends issued to the Company. The net income is adjusted to reflect the amortization of the fair value adjustments related to the Company's share of the net identifiable assets of Medison acquired and their tax impact.

This selected information is derived from our Interim Financial Statements.

	Q3-19	Q2-19	Q1-19	Q4-18	Q3-18	Q2-18	Q1-18	Q4-17
Carrying value of investment	**73,729**	74,623	75,402	79,145	79,031	78,990	77,697	75,983
Amortization of FMV adjustments	**(1,377)**	(1,378)	(1,378)	(1,377)	(1,378)	(1,378)	(1,378)	(1,529)
Share of net income (loss), net of FMV adjustment	**128**	(372)	692	114	89	(151)	503	341
Dividends	**—**	—	4,159	—	—	—	—	—

The Company is presenting select financial information derived from Medison's consolidated financial statements, excluding amortization of fair value adjustments on acquisition in ILS using Israeli GAAP converted into IFRS in CAD for information purposes:

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-19	Q2-19	Q1-19	Q4-18	Q3-18	Q2-18	Q1-18	Q4-17
Revenues	**77,735**	74,761	75,303	72,650	63,482	64,260	60,259	57,399
Net income	**5,324**	3,558	7,322	5,262	5,189	4,352	6,653	6,614

RISK MANAGEMENT

Section 11

11.1 Currency Risk

Knight holds a significant portion of its net financial assets in US$ and EUR which results in financial risk due to fluctuations in the value of the currencies relative to the Canadian dollar. Assuming that all other variables remain constant, a 5% change in the Canadian dollar against the US$ and EUR would have resulted in a change in the statement of income and comprehensive income of $11,555 and $1,329, respectively.

Subsequent to September 30, 2019, the Company entered into forward contracts which is the equivalent to holding BRL 820,662 in terms of financial risk. The forward contracts will be used to fund the acquisition of GBT. As a result, the Company is exposed to additional currency risk due to fluctuations of the BRL relative to the Canadian dollar.

11.2 Equity Price Risk

Equity price risk arises from changes in market prices of the equity and fund investments and derivatives. The carrying values of investments subject to equity price risk are $131,348 as at September 30, 2019 (December 31, 2018: $98,553). The Company monitors its equity investments for impairment on a periodic basis and at least every reporting period. Market prices are subject to fluctuation and, consequently, the amount realized in the subsequent sale of an investment may significantly differ from the reported market value. Fluctuation in the market price of a security may result from perceived changes in the underlying economic characteristics of the investee, the relative price of alternative investments and general market conditions. Furthermore, amounts realized in the sale of a particular security may be affected by the relative quantity of the security being sold. The Company's Board of Directors regularly reviews and approves equity investment decisions.

11.3 Interest Rate Risk

The Company is subject to interest rate risk on the interest income generated on its cash, cash equivalents and marketable securities. Details regarding maturity dates and effective interest rates are described in notes 3 and 4 of the Interim Financial Statements. Assuming that all other variables remain constant, a 1% decline on the interest rate generated on cash, cash equivalents and marketable securities would have result in a reduction of interest income of $7,001 over a one-year period.

11.4 Liquidity Risk

The majority of the Company's financial liabilities are short term in nature. The Company generates sufficient cash from operating activities to fund its operations and fulfil its obligations as they become due. The Company has sufficient funds available through its cash, cash equivalents and marketable securities, should its cash requirements exceed cash generated from operations to cover all financial liability obligations. As at September 30, 2019, there were no restrictions on the flow of these funds nor have any of these funds been committed in any way, except as set out in note 18 of the Interim Financial Statements.

11.5 Credit Risk

The Company considers its maximum credit risk to be $168,182 (December 31, 2018: $125,270) which is the total of the following assets; trade and accounts receivable, interest receivable, loans receivable and investment in funds.

The marketable securities and cash equivalent balances are subject to minimal risk of changes in value and are invested in institutions with a S&P or DBRS credit rating of A or R1(low) or better which are invested in the following:

(In thousands of Canadian dollars, except for share and per share amounts)

- three Canadian financial institutions & two foreign affiliates of Canadian financial institutions
- one Canadian corporation
- five Canadian credit unions

The Company is exposed to credit risk from its customers and continually monitors its customers' credit. It establishes the ECL based upon days past due and the likelihood of collection for each customer. The credit risk on loans and interest receivable is due to the risk of insolvency or operational failure of the partners in the strategic lending transaction. The Company has assessed that loans measured at FVTPL have S&P credit ratings between CCC+ and CC. The Company also has a credit risk on its investment in funds and derivatives which are held through venture funds or issued by a counterparty.

11.6 Risk Factors

For a detailed discussion of additional risk factors, please refer to the Company's Annual Information Form for the year ended December 31, 2018 on SEDAR at www.sedar.com.

ADDITIONAL INFORMATION

Section 12 – Selected Quarterly Financial Information

This selected information is derived from our Interim Financial Statements.

	Q3-19	Q2-19	Q1-19	Q4-18	Q3-18	Q2-18	Q1-18	Q4-17
Revenues	**4,030**	3,204	2,956	3,888	3,220	2,238	3,154	2,544
Net (loss) income	**(2,959)**	18,956	5,189	221	12,930	4,019	6,909	7,145
EPS								
Basic	**(0.021)**	0.133	0.036	0.002	0.091	0.028	0.048	0.050
Diluted	**(0.021)**	0.132	0.036	0.002	0.090	0.028	0.048	0.050
Cash, cash equivalents and marketable securities	**700,092**	745,272	748,411	787,062	775,046	806,746	802,425	765,033
Total assets	**1,022,261**	1,074,371	1,058,191	1,051,832	1,041,506	1,029,133	1,016,853	1,005,983
Total non-current liabilities	**5,812**	6,339	5,440	4,615	3,261	1,127	1,171	515

The Company has not paid dividends on its common shares and does not anticipate declaring any dividends in the near future.

Section 13 – Outstanding Share Data

The table below summarizes the share data:

As at	**November 12, 2019**	**September 30, 2019**
Common Shares	135,629,136	135,717,148
Stock Options	4,774,734	4,774,734
Warrants	406,126	406,126

On July 8, 2019, the Company announced that the Toronto Stock Exchange approved its notice of intention to make a NCIB. A copy of the notice to commence the NCIB is available without charge by contacting the Company by email at info@gudknight.com or by phone at 514-484-4483.

Under the terms of the NCIB, Knight may purchase for cancellation up to 12,053,693 common shares of the Company which

represented 10% of its public float as at July 2, 2019. The NCIB commenced on July 11, 2019 and will end on the earlier of July 10, 2020 or when the Company completes its maximum purchases under the NCIB.

During the quarter ended September 30, 2019, the Company has purchased 7,174,137 common shares, for an aggregate cash consideration of $54,283, which was allocated between share capital and retained earnings. As at September 30, 2019, 12,900 of the common shares purchased remain to be cancelled.

As at November 12, 2019, Knight has purchased a total of 7,249,249 common shares for an aggregate cash consideration of $54,830 and has 135,629,136 common shares outstanding.

Section 14 – Use of Proceeds from Financing

To date, Knight has raised net proceeds of approximately $685,000 from five public offerings. In our short form prospectuses related to the offerings, Knight disclosed that its intent was to use a substantial portion of the net proceeds (i) for potential acquisitions of (a) in-licensing of over-the-counter and prescription pharmaceutical products and targeted promotion of these products, and (b) specialty pharmaceutical businesses in select international markets, (ii) for financing of other life sciences companies in Canada and internationally as well as for investments in funds focused in the life sciences sector, and (iii) the remainder for general corporate purposes.

As at September 30, 2019, Knight had deployed and invested or committed to deploy and invest over $350,000 for the purposes disclosed in the prospectuses, as described above. Pending the application of the remainder of the net proceeds, Knight has invested part of the net proceeds in short-term investment-grade securities and bank deposits, and holds the remainder in cash. Knight anticipates that it has sufficient funds available to achieve its business objectives and milestones as listed in the prospectuses.

Subsequent to the quarter ended September 30, 2019, the Company has entered into a definitive agreement to acquire 51.2% of GBT. For further details refer to Section 27.

Section 15 – Payment of Dividends

The Company has not paid dividends on its common shares since inception and does not anticipate declaring dividends in the foreseeable future. Knight's current policy is to retain earnings to finance the acquisition and development of new products and to reinvest in the growth of the Company. Any future determination to pay dividends is at the discretion of the Company's Board of Directors and will depend on the Company's financial condition, results of operations, capital requirements and other such factors as the Board of Directors of the Company deems relevant.

Section 16 – Product Pricing Regulation on Certain Patented Drug Products

All patented drug products that form part of Knight's portfolio of products are subject to pricing regulation by the PMPRB, a federal agency tasked with ensuring that prices of patented medicines are not excessive. For new patented products, the maximum non-excessive price in Canada is limited to a range with a lower bound set by the prices of existing comparable drugs sold in Canada and an upper bound set by the median prices for the same drug sold in a specified set of developed comparator countries. For existing patented products, prices cannot be increased annually by more than a factor based on Statistics Canada's Consumer Price Index. The PMPRB monitors compliance through a review of the average transaction price of each patented drug product as reported by pharmaceutical companies like Knight on a semi-annual basis. The PMPRB may from time to time deem certain of Knight's existing or future patented products to be excessively priced based on the application of its empowering legislation and regulations, including those related to price increases, the comparative assessment of new products and reductions in the highest price in international reference countries. Such determinations by the PMPRB may have a material adverse effect on Knight's financial condition and results of operations or cash flows.

The Canadian federal government has made a commitment to reduce the cost of prescription drug pending in Canada. On December 2, 2017, Health Canada published the following proposed key changes:

- changes in the comparator countries used to determine price ceilings. The changes include removal of the US (which generally has the highest international drug prices) and Switzerland and addition of seven new countries judged to have similar consumer protection-oriented mandates and relative wealth as Canada;
- new, economics-based price regulatory factors to allow the PMPRB to regulate based on the value of a medicine and its impact on the health care system; and,
- changes to certain reporting requirements, including reporting all discounts and rebates provided to third-party payers, such as provincial drug plans.

On August 21, 2019, the federal government published the final regulations governing the PMPRB. The new regulations include eleven countries as comparators and will come into force on July 1, 2020. Furthermore, the draft guidelines to clarify the mechanism and other details of the implementation of the amended regulations are expected to be released in Q4-19.

The regulatory changes to the PMPRB may have a significant adverse effect on the price of patented drugs sold by the Corporation in Canada and may limit the Corporation's ability to in-license and launch products in Canada due to more restrictive pricing regulations.

Section 17 – Financial Instruments

The Company's investment policy regulates the investment activities relating to cash resources. The Company invests in strategic investments in the form of equity funds, debt funds, equity or liquid investment securities with varying terms to maturity, selected with regard to the expected timing of investments and expenditures for continuing operations, and prevailing interest rates.

Section 18 – Off-balance Sheet Arrangements

The Company's off-balance sheet arrangements consist of contractual obligations and agreements for development, sales, marketing and distribution rights to innovative drug products. The effect of terminating these arrangements under normal operating circumstances consists of an effective transition of the remaining responsibilities and obligations to the licensor under agreed upon time frames and conditions. Please refer to note 18 of the Interim Financial Statements for the period ended September 30, 2019 for additional information. Other than these contractual obligations and commitments, the Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's financial condition, changes in revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Section 19 – Commitments

In the normal course of business, the Company secures development, sales, marketing and distribution rights to innovative drug products requiring royalties or product payments considered normal operating commitments and as such not included herein. The Company has entered into various agreements which include contractual obligations extending beyond the current year. These obligations are classified into three major categories: fund commitments, milestones and purchase commitments, equity and loan commitments and acquisition commitments. The commitments of the Company as at September 30, 2019 are as follows:

[i] Fund commitments

As at September 30, 2019, under the terms of Company's agreements with life sciences venture capital funds, $45,830 (December 31, 2018: $61,973), including $12,835 [US$9,692] and $9,159 [EUR 6,344], may be called over the life of the funds (based on the closing foreign exchange rates).

As at November 12, 2019, $44,638 remains to be called by life science venture capital funds.

[ii] Milestones and purchase commitments

Under certain agreements, Knight may have to pay additional consideration should the Company achieve certain sales volumes or if certain milestones are met, such as regulatory approval in Canada. The Company may have to pay up to $98,306 including $30,862 [US$23,305] and $505 [EUR 350] upon achieving certain sales volumes, regulatory or other milestones related to specific products.

In addition, Knight has a commitment to purchase up to $2,020 [EUR 738 and US$721], of inventory for pharmaceutical products during the five-year period after their respective commercial launch. Furthermore, Knight has committed to certain sales force and marketing spend obligations during the five-year period after the commercial launch of one of its products.

[iii] Equity and loan commitments

Subject to a loan agreement with a borrower, Knight has committed to up to a maximum equity investment of $3,311 [US$2,500] to participate in the initial public offering of the borrower.

Subject to the Moksha8 Financing Agreement, Knight has committed to loan up to an additional $13,905 [US$10,500] should the borrower meet certain pre-defined profitability targets over its 2020 to 2021 financial years.

[iii] Acquisition commitment

Subsequent to the quarter ended September 30, 2019, the Company has entered into a definitive agreement to acquire 51.2% of GBT. For further details refer to Section 27.

Section 20 – Related Party Transactions

Pharmascience Inc., a company related to the Company's CEO, provided administrative services of approximately $11 to the Company for the nine-month period ended September 30, 2019.

Section 21 – Segment Reporting

The Company has one reportable segment, and its principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing innovative pharmaceutical products, consumer health products and medical devices in Canada and select international markets.

For the three and nine-month period ended September 30, 2019, revenues from products sold in Canada and internationally were $551 and $3,479 (2018: $485 and $2,735) and $1,727 and $8,463 (2018: $1,691 and $6,921) respectively. Furthermore, non-current operating assets consisting of property and equipment, intangible assets, investment in associate and other receivables held in Canada and internationally were $134,635 and $1,303 respectively (December 31, 2018: $118,114 and $2,610).

(In thousands of Canadian dollars, except for share and per share amounts)

Section 22 – Significant Accounting Estimates and Assumptions

The preparation of the Company's consolidated financial statements requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts or revenues and expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Our significant accounting estimates and assumptions are reported in note 3 of our 2018 Annual Financial Statements and note 2.2 of our Interim Financial Statements.

Section 23 – Accounting Pronouncements Adopted in 2019

The Company applied IFRS 16 for the first time effective January 1, 2019. The nature and effect of the changes as a result of adoption of these new accounting standards are described below. Refer to note 2 of the Interim Financial Statements for further details on the new accounting standards adopted. The Company has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.

Impact of transition to IFRS 16

The Company adopted IFRS 16 using the full modified retrospective approach on January 1, 2019. The Company elected to not separate lease and non-lease components from payments and account for both as a single lease component. As a result of the transition, the Company recognized $1,139 of lease liabilities and $1,121 of right-of-use assets and with no net impact on opening retained earnings. The following table summarizes the effect of transition to IFRS 16 on the Company's condensed consolidated statement of financial position as at January 1, 2019.

	December 31, 2018	Transition Impact	January 1, 2019
	$	$	$
ASSETS			
Property and equipment	794	1,121	1,915
CURRENT LIABILITES			
Lease Liabilities	—	273	273
NON-CURRENT LIABILITES			
Lease Liabilities	—	866	866

The following table reconciles the Company's operating lease commitments as at December 31, 2018, to the lease obligations recognized on initial application of IFRS 16.

	$
Operating lease commitments at December 31, 2018	**1,125**
Adjustments[1]:	
Present value adjustment on lease commitment	(60)
Extension options expected to be exercised not included in lease commitments	74
Lease obligations as at January 1, 2019	**1,139**

[1] Discounted using IBR of 3.00%

IFRIC 23 Uncertainty over Income Tax Treatment

In June 2017, the IASB released IFRIC 23 Uncertainty over income tax treatments ("IFRIC 23"), which is effective on January 1, 2019. IFRIC 23 clarifies accounting for income taxes when tax treatments involve uncertainty that affects the application of IAS 12 Income Taxes and does not apply to taxes outside the scope of IAS 12, nor does it specifically include

requirements relating to interest and penalties associated with uncertain tax treatments. It specifically addresses whether an entity considers each tax treatment independently or collectively, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit or loss, tax bases, unused tax losses, unused tax credits and tax rates and how an entity considers changes in facts and circumstances. The Company has concluded that IFRIC 23 has no material impact on its consolidated financial statements.

Section 24 – Disclosure Controls and Procedures

The Company is committed to providing timely, accurate and balanced disclosure of all material information about the Company and to providing fair and equal access to such information. Management is responsible for establishing and maintaining its DC&P to ensure that information used internally and disclosed externally is complete and reliable. Due to the inherent limitations in all control systems, an evaluation of controls can provide only reasonable, not absolute assurance, that all control issues and instances of fraud or error, if any, within the Company have been detected. Management continues to evolve and enhance its system of controls and procedures.

Section 25 – Internal Control Over Financial Reporting

The Company's management is responsible for establishing and maintaining adequate ICFR. The Company has designed ICFR to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with IFRS.

All control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention or overriding of the controls or procedures. As a result, there is no certainty that our DC&P or ICFR will prevent all errors or all fraud.

During 2019, there was no significant changes in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect the Company's internal controls over financial reporting.

Section 26 – Litigations

On March 21, 2019, the Company filed a legal action in Lod, Israel (District Court Center-Lod) against Medison, Medison's CEO Meir Jakobsohn, and Tzalir Holdings Ltd., Mr. Jakobsohn's personal holding company. The Company, in its capacity as a shareholder of Medison, is seeking to prevent Mr. Jakobsohn from using Medison's cash reserves to fund an activist campaign against the Company. The Company asserts that Medison's conduct constitutes shareholder discrimination and is improper and oppressive under Israeli companies law. The defendants have filed a statement of defence and the Company has filed a statement of response to Medison's defence.

On March 28, 2019, Medison filed a separate legal action in Lod, Israel (District Court Center-Lod) against the Company and its chief executive officer, Jonathan Ross Goodman. Medison is asking the court to remove Mr. Goodman from Medison's board of directors as the Company's nominee director and to order the Company appoint another individual to replace him. Medison alleges that Mr. Goodman is in a conflict of interest. The Company intends to vigorously contest the lawsuit. The Company has filed a statement of defence and Medison has filed a statement of response to the Company's defence.

A pre-trial hearing, originally set for June 12, 2019, was rescheduled to November 10, 2019 and was subsequently postponed to January 15, 2020, to deal with procedural matters with respect to both actions as well as a separate action filed by Mr. Goodman in his capacity as a director of Medison.

Section 27 – Subsequent Events

[i] Biotoscana Investments S.A.

GBT is an established and profitable Latin American pharmaceutical company headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region. GBT is the LATAM partner of choice for multinational pharmaceutical companies and has a diversified portfolio of innovative products as well as a branded generics portfolio. For the trailing twelve-month period ending June 30, 2019, GBT generated revenue[2] of $240,000[1] [BRL 754,000] and adjusted EBITDA[3] of $49,000[1] [BRL 154,000] with Brazil, Argentina and Colombia representing about 86% of revenues.

On October 18, 2019, the Company entered into a share purchase agreement to acquire 51.2% of GBT (B3: GBIO33) at BRL 10.96 per share or approximately $189,000[1] [BRL 596,000] ("Share Purchase Agreement"). The transaction is expected to close on November 29, 2019, upon which 80% of the purchase price will be paid to the sellers and the remaining 20% will be deposited in an escrow account as a guarantee against the sellers' indemnification obligations. The escrow will be released equally over a period of three years, net of claims, according to the terms and conditions of the Share Purchase Agreement.

Following the closing of the Share Purchase Agreement, Knight will launch a mandatory tender offer to acquire the remaining 48.8% common shares of GBT ("Tender Process") which trade as Brazilian Depository Receipts ("BDRs") on Brasil Bolsa Balcão S.A. ("B3"), in Brazil. Assuming all public shareholders tender their shares, Knight expects to pay approximately $180,000[1] [BRL 568,000]. The Tender Process is expected to take 4 to 8 months from launch to close. Following the close of the Share Purchase Agreement and the Tender Process, Knight expects to have paid a total of approximately $369,000[1] [BRL 1,164,000] for the common shares and an additional $49,000[1] [BRL 154,000] to cover GBT's net financial debt.

[ii] Netildex

On October 23, 2019, Netildex® was approved by Health Canada for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate.

[iii] Joyesta

On October 30, 2019, Knight announced that Joyesta™ was accepted for review by Health Canada for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency to Health Canada.

[1]Amounts translated at the BRL to CAD closing exchange rate as of October 18, 2019 of 3.145. The price in Canadian dollars will vary depending on the exchange rate.
[2]Excluding the impact of hyperinflation accounting for Argentina.
[3]Adjusted EBITDA does not have a standard meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS. Adjusted EBITDA has been calculated based on the definition disclosed by GBT in their Financial Statements, adjusted for the impact of IFRS 16 and the impact of hyperinflation accounting for Argentina. Per GBT, EBITDA is defined as operating profit before financial expenses and income taxes, plus amortization and depreciation. Adjusted EBITDA refers to EBITDA as adjusted to remove accounting effects and costs associated with some non-recurring income and expenses considered by management to be non-recurring and exceptional in nature.